Search - tctmd.com

Displaying 61 - 80 of 105

Sort: Relevancy | Date

‘People Are Pretty Optimistic’ as Renal Denervation’s Comeback Continues

News Daily News

‘People Are Pretty Optimistic’ as Renal Denervation’s Comeback Continues

June 24, 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

Infective Endocarditis Related to Injecting Opioids on the Rise in Ontario

News Daily News

Infective Endocarditis Related to Injecting Opioids on the Rise in Ontario

January 28, 2019

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

November 11, 2018

News Industry News

Medicure Announces FDA Approval of Acute Care Cardiovascular Drug Sodium Nitroprusside Injection

August 14, 2018

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

News Conference News EAS 2018

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

Yael L. Maxwell

May 14, 2018

Botox Injections Around the Heart Have Lasting Impact on Suppressing A-fib After CABG

News Conference News HRS 2018

Botox Injections Around the Heart Have Lasting Impact on Suppressing A-fib After CABG

May 14, 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 05, 2018

News Industry News

Baxter Announces U.S. FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin

January 22, 2018

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

Technique for Diluting the Blood During Primary PCI to Prevent Reperfusion Injury Seems Safe, Feasible

News Daily News

Technique for Diluting the Blood During Primary PCI to Prevent Reperfusion Injury Seems Safe, Feasible

July 04, 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

News Conference News ISET 2017

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

February 15, 2017

News Conference News AHA 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

November 28, 2016

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

News Daily News

Pfizer Discontinues Investigational PCSK9 Inhibitor Bococizumab

Michael O'Riordan

November 01, 2016

A Dose for Doing: Healthcare Providers and Exercise Specialists Struggle With Prescribing Physical Activity

News Features

A Dose for Doing: Healthcare Providers and Exercise Specialists Struggle With Prescribing Physical Activity

Yael L. Maxwell

October 24, 2016

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Yael L. Maxwell

August 29, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.